EP1458252B1 - Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity - Google Patents

Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity Download PDF

Info

Publication number
EP1458252B1
EP1458252B1 EP02795287A EP02795287A EP1458252B1 EP 1458252 B1 EP1458252 B1 EP 1458252B1 EP 02795287 A EP02795287 A EP 02795287A EP 02795287 A EP02795287 A EP 02795287A EP 1458252 B1 EP1458252 B1 EP 1458252B1
Authority
EP
European Patent Office
Prior art keywords
nicotine
tobacco
composition according
release
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02795287A
Other languages
German (de)
French (fr)
Other versions
EP1458252A2 (en
Inventor
Henri Hansson
Lars Hovgaard
Christer Spegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galenica AB
Original Assignee
Galenica AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galenica AB filed Critical Galenica AB
Publication of EP1458252A2 publication Critical patent/EP1458252A2/en
Application granted granted Critical
Publication of EP1458252B1 publication Critical patent/EP1458252B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B13/00Tobacco for pipes, for cigars, e.g. cigar inserts, or for cigarettes; Chewing tobacco; Snuff
    • AHUMAN NECESSITIES
    • A24TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24BMANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10Chemical features of tobacco products or tobacco substitutes
    • A24B15/16Chemical features of tobacco products or tobacco substitutes of tobacco substitutes

Definitions

  • the present invention relates to a novel composition for the use as snuff in the oral cavity, the composition comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble.
  • a novel composition enables a selective release of e.g. nicotine while it at the same time reduces the release of substances, which normally lead to unwanted side effects.
  • the novel compositions may be used as a healthier alternative to snuff and other tobacco products such as, e.g., cigarettes, cigars and pipe.
  • the invention also relates to methods for giving up smoking, reducing nicotine craving, reducing side effects normally related to smoking and snuffing of tobacco as well to a method for the preparation of a composition according to the invention.
  • various buffer systems may be added, e.g. carbonates.
  • the moist snuff is either packed loosely, as bulk in a box or as single doses in small non-woven bags. A number of the filled and sealed bags are then packed in a box.
  • the moist snuff as a single dose has become popular due to the ease of use compared to the bulk product.
  • the popularity of moist snuff is most probably due to its pharmacological nicotine absorption profile.
  • the dose of nicotine and speed of absorption is approximately 10 ng per ml over 10 minutes.
  • Plasma nicotine concentrations rapidly increase within the first few minutes of the use of snuff and reach levels comparable to those obtained from smoking cigarettes within 30 min of use. Measurements of plasma nicotine concentrations after a single day of moist snuff consumption also yielded levels similar to cigarette use.
  • the kinetics is slightly slower compared to the kinetics when smoking tobacco, such as e.g. cigarettes and cigars; however, the overall amount of nicotine absorbed is higher when snuff is employed.
  • snuff is the vast number of compounds, more or less harmful to the body, e.g. different tobacco-specific nitrosamines, which are compounds known to cause different diseases such as, e.g., gastro-intestinal disorders and cancer.
  • US 4,141,369 describes a method of inhaling the nicotine from tobacco without combustion of the tobacco.
  • Another way of avoiding the harmful substances contained in tobacco is to substitute tobacco with nicotine.
  • Various devices have also be constructed in order to deliver nicotine from a tobacco composition placed in the oral cavity:
  • US 5,346,734 describes a perforated latex oral pouch for loose, moist snuff, the pouch serving as a barrier to avoid direct physical contact between the tobacco product and the gum.
  • the pouch has to be filled by the user, cut to fit the mouth cavity of the user and is re-usable.
  • US 6,162,516 describes a shield, which also has to be filled with snuff by the user, the shield acting as a barrier to reduce tobacco contact with the sensitive inner cheek lining and gum surfaces while using snuff.
  • the present invention provides a composition wherein the release of nicotine from snuff can be designed freely, even though the release of unwanted and harmful substances from the tobacco is dramatically reduced.
  • the present invention provides a composition for use in the oral cavity comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble.
  • the gist of the invention is the employment of a membrane material which makes it possible to deliver nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof in a predetermined manner and - at the same time - has the properties of withholding the substances which are unwanted to such a degree that the side-effects normally observed in connection with the use of snuff in the oral cavity are dramatically reduced.
  • the tobacco used in the novel snuff composition according to the invention may be natural tobacco leaves in order to preserve the authentic taste and feeling of tobacco.
  • the tobacco plant belongs to the family Solanaceae and the genus Nicotiana. More than 60 tobacco species exists, the most commonly used in smoking or snuffing tobacco products being Nicotiana tabacum and Nicotiana rustica.
  • To manufacture moist snuff the tobacco, which typically has a content of from about 1% to 8% nicotine, is dried, milled and mixed with a fermentative solution. The mixture is then fermented, typically for 5 days to 4 weeks at elevated temperature. After this the tobacco mass is mixed with a suitable buffer, such as e.g.
  • the water content in the final product may lie in the range from about 10 % to about 60 %.
  • additional compounds may be added, such as e.g. sweeteners, aroma substances and other taste additives, detergents and preservative, release modifying agents, and other liquids such as oil, organic solvents and herbal extracts.
  • the natural fermented tobacco may be partly substituted with a tobacco substitute, such as, e.g., nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate.
  • a tobacco substitute such as, e.g., nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate.
  • some additional filler may be added, such as, e.g., non-digestible fibers.
  • the tobacco and/or tobacco substitute may preferably have a content of nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof, from about 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15% w/w, from about 0.1% w/w to about 10% w/w, from about 0.1% w/w to about 9% w/w or from about 0.1% w/w to about 8% w/w.
  • a content of nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof from about 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15%
  • the tobacco and/or tobacco substitute is enclosed in a membrane material.
  • the membrane material may comprise one or more membranes.
  • membrane describes a thin polymeric film having natural pores and acting as a selective permeability barrier. The term does not include papermade material or polymeric materials in which not-naturally occurring openings have been made.
  • At least one of the membranes may be water-insoluble to prevent spreading of the snuff in the oral cavity, and to maintain the beneficial properties of the selective membrane material during use, with respect to the withholding of unwanted substances.
  • At least one of the membranes may be water permeable in order to allow water to diffuse into the encapsulated tobacco and/or tobacco substitute and to allow e.g. nicotine to diffuse through the polymeric membrane material and thus becoming available for absorption.
  • the membranes may have a predominantly hydrophilic or hydrophobic nature.
  • the hydrophilic or hydrophobic nature of the membrane has an effect on the release of substances such as, e.g., nicotine through the membrane, since the flow of substances through the membrane is dependent on the ability of the membrane to hydrate, e.g. create hydro-channels through the membrane. These hydro-channels are a prerequisite for molecular transport when dry polymeric membranes are used.
  • the flow of hydrophilic substances through a hydrophobic membrane is slower compared to a hydrophilic membrane. This is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water.
  • One or more of the membranes used for making the composition may be a synthetic or semi-synthetic membrane.
  • a synthetic or semi-synthetic membrane As is given some examples of natural, synthetic and semi-synthetic hydrophilic and hydrophobic membranes, which may be used in a novel snuff composition according to the invention.
  • membranes are membranes made of cellulose acetate and derivates thereof, carboxymethyl cellulose membranes, polycellulose ester membranes, other cellulose derivatives such as, e.g., ethylcellulose, propylcellulose, polyethylene membranes, polypropylene membranes, polystyrene membranes, polyvinyl chloride membranes, polyvinyl acetate membranes, membranes made of polymers of methacrylates and acrylates, natural rubber membranes, polycarbonate membranes, polyethylene terephthalate membranes, polyester membranes, polyamide membranes and nylon membranes.
  • cellulose acetate and derivates thereof such as, e.g., ethylcellulose, propylcellulose, polyethylene membranes, polypropylene membranes, polystyrene membranes, polyvinyl chloride membranes, polyvinyl acetate membranes, membranes made of polymers of methacrylates and acrylates, natural rubber membranes, polycarbonate membranes, polyethylene tere
  • At least the outer membrane in the membrane material enclosing the tobacco and/or tobacco substitute may be made from a biocompatible and physiologically acceptable polymeric material, since the novel snuff composition has to be placed close to or in contact with the mucous membrane in the oral cavity during use.
  • At least one of the membranes in a membrane material may be surface treated with e.g. polycarbophils to obtain a bioadhesiveness of the novel snuff composition in the oral cavity.
  • the molecular weight cut off of the membrane material used in the novel snuff composition may be varied to obtain a desired release of nicotine and other substances through the membrane material.
  • the molecular weight cut-off of a membrane is defined as the molecular weight of the smallest molecule of which 90 % will be prevented from permeating the membrane.
  • the exact permeability of a molecule is dependent on the shape, the degree of hydration and the charge of the molecule.
  • At least one of the membranes comprising the membrane material may have a molecular weight cut-off from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500; or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25,000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
  • a molecular weight cut-off from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500; or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25,000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
  • the release of nicotine and/or other substances through the membrane material is also dependent on the thickness of the membrane materiel.
  • the diffusion process of molecules through the membrane is decreased when the membrane thickness is increased and vice versa.
  • the thickness of the membrane material may be varied in respect of obtaining a desired release of nicotine and other substances through the membrane material.
  • the lower limit for the membrane material thickness is determined by what is possible from a practical point of view, and the upper value is restricted by what will allow a comfortable fit of the novel snuff composition in the oral cavity of the user.
  • At least one of the membranes comprising the membrane material may have a thickness of from 2 to about 200 ⁇ m such as, e.g., from about 5 to about 100 ⁇ m, from about 7.5 to about 50 ⁇ m, from about 7.5 to about 40 ⁇ m, from about 7.5 to about 35 ⁇ m, from about 7.5 to about 30 ⁇ m or from about 7.5 to about 25 ⁇ m.
  • nicotine or a nicotine derivative, analog, salt, solvate or a mixture thereof, selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate, has to be released from the composition.
  • the release profile may be designed with respect to the rate and amount of nicotine and unwanted substances released by the membrane.
  • the release of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from a novel snuff composition may be designed to be released in a sufficient amount and/or a sufficient rate to enable a desired effect and on the other hand be designed to retain substances, which normally give rise to side-effects, such as, e.g., nitrosamines, and/or to release such substances in a substantially low amount and/or at a substantially slow rate.
  • the Impurity Index- IPI - is introduced.
  • the IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm as described in Example 2, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. In other words, a low IPI reflects that a large amount of nicotine is released through the membrane compared to the amount of unwanted substances.
  • the impurity index IPI is at the most 3.0 such as, e.g. at the most 2.75, at the most 2.5, at the most 2.0, at the most 1.75, at the most 1.5, at the most 1.5 or at the most 1.4 when measured after 90 min.
  • the release profile of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the invention could e.g., be fast and equivalent to the release of nicotine from the commercially available moist snuff, while maintaining a low IPI value, i.e. limiting the release of unwanted substances.
  • a composition according to the invention can be designed to release nicotine and/or a derivative, analog, salt, solvate or mixture thereof in a controlled manner such as, e.g., fast (faster than from the reference product employed in the examples herein), relatively fast (i.e. similar or almost similar to the reference product employed in the examples herein), delayed (i.e. with a lag time in which period no nicotine is released followed by a release of nicotine), prolonged or sustained (i.e. a relatively slower release than the reference product to avoid any peak concentration and to obtain a relatively constant plasma concentration of nicotine after application).
  • fast fast
  • relatively fast i.e. similar or almost similar to the reference product employed in the examples herein
  • delayed i.e. with a lag time in which period no nicotine is released followed by a release of nicotine
  • prolonged or sustained i.e. a relatively slower release than the reference product to avoid any peak concentration and to obtain a relatively constant plasma concentration of nicotine after application.
  • the release of nicotine or a derivative, analog, salt, solvate or a mixture thereof may be delayed compared to the commercially available moist snuff, to mimic the effect of nicotine replacement products such as, e.g., patches.
  • the release of nicotine or a derivative, analog, salt, solvate or a mixture thereof may be determined by the release test described in Example 1, but other suitable methods for determining the release of nicotine may also be used, i.e. the embodiments of the invention described below referrer to Example 1 without limiting the relevant release tests to the one described in Example 1.
  • the tobacco and/or tobacco in combination with a tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
  • the tobacco and/or tobacco substitute composition may be designed so that at the most 25% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
  • the tobacco and/or tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 120 min when subject to the release test described in Example 1 below.
  • release profiles for compositions according to the invention are described as %w/w released of total nicotine content as a function of time, measured at 0, 3, 30, 90 and 180 minutes.
  • the release profiles according to the invention also includes profiles described by only one or any combination of the values below, i.e. a release profile according to the invention could be defined by e.g. the %w/w release of nicotine at 3 minutes and 90 min, or at 3 and 90 and 180 minutes, or at 90 and 180 minutes or any possible combination of the values shown below.
  • a composition according to the invention is suitable designed to release nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or tobacco in combination with the tobacco substitute with the following characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 20 such as, e.g., from about 0 to about 15 or from about 0 to about 10, 3 from about 0 to about 40 such as, e.g., from about 0 to about 35, from about 0 to about 30, from about 0 to about 25, from about 0 to about 20, 30 from about 2 to about 100, such as, e.g., from about 2 to about 90, from about 2 to about 80, from about 2 to about 70, from about 2 to about 65, from about 2 to about 60, from about 5 to about 60, from about 5 to about 55, from about 7.5 to about 55 or from about 10 to about 50, op til 100 90 from about 10 to about 100 such as, e.g., from about 10 to about 95, from about
  • a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 15 3 from about 1 to about 25 30 from about 7.5 to about 55 90 from about 35 to about 80 180 from about 65 to about 100 and the release is determined as described herein in Example 1.
  • a composition according to the invention releases, nicotine and/or derivative, analog, salt or solvate thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 10 to about 50 90 from about 40 to about 90 180 from about 70 to about 100 and the release is determined as described herein in Example 1.
  • a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 30 to about 50 90 from about 65 to about 90 and the release is determined as described herein in Example 1.
  • membrane material properties such as hydrophobicity, hydrophilicity, molecular weight cut-off and membrane thickness may be used in designing a desired release profile for nicotine or a derivative, analog, salt, solvate or mixture thereof.
  • a multi-layer membrane is e.g. designed to contain one membrane material being hydrophilic and a second membrane material being lipophilic. Both membrane components are chosen in such a manner that the membrane material has a molecular cut off large enough for the relatively small nicotine molecule to pass through with ease.
  • amphiphilic nature of nicotine enables it to pass both hydrophilic and hydrophobic materials while a majority of both hydrophilic and lipophilic unwanted and harmful substances are excluded from permeation through the membrane material.
  • Many other combinations of different types of membranes are of course possible and based on the disclosure herein a skilled person will know how to chose different membranes in order to obtain a suitable release.
  • compositions according to the invention are a composition wherein the membrane material is a bi-layer membrane with one membrane being preferentially hydrophilic and one membrane being predominantly hydrophobic. Both membranes possess high permeability to nicotine while maintaining low aqueous pore diffusion.
  • the release profile of nicotine could either be identical to the release profile of original snuff or it could be designed to have a prolonged or sustained release. The unwanted and harmful substances from the tobacco should substantially be maintained inside the membrane.
  • a composition according to the invention may attain all possible sizes and shapes, such as, e.g. round, circular, oblong, elliptical, square, rectangular or trapezoidal.
  • the shape and/or size chosen may be such as to allow a comfortable fit in the oral cavity.
  • the location in the oral cavity of a composition according to the invention may be centered or to the sides under the upper front lip, centered or to the sides under the lower front lip, under the tongue or in the cheeks.
  • the invention also relates to use of a composition according to the invention as a smoke substitute and it can be used by persons who suffer from nicotine craving or who want to give up or reduce smoking.
  • the content of tobacco and/or a tobacco substitute is adjusted to the individual purposes and it is possible to design a kit comprising compositions according to the invention with different concentrations of tobacco and/or a tobacco substitute.
  • Such compositions in a kit could e.g. contain compositions with a decreasing content of tobacco or nicotine.
  • Membranes made of regenerated cellulose acetate dialysis tubing with varying MW cut-off together with vinyl and polyethylene membranes with various thicknesses were tested with respect to the diffusion profiles over the membranes of nicotine released from tobacco.
  • snuff tobacco SVENSKT SNUS, GOTHIATEK, General
  • PBS phosphate buffered saline according to Ph. Eur.
  • PBS with a pH of 6.6 was placed in the receiver chamber.
  • the cells of the diffusion chamber were kept at a temperature of 37°C ⁇ 0.5°C by attachment to a water bath. The temperature control was made in order to simulate the environment of the oral cavity.
  • Diffusion profiles were constructed by sampling from the receiver chamber at 0, 3, 30, 60, 90, 120, (110 min for the polyethylene membrane) and 180 min after the start of the diffusion experiment.
  • the concentration of nicotine in the receiver chamber was measured by HPLC, using a C-18, 5 ⁇ , 4.5 mm x 15 cm column, employing a mobile phase consisting of 70 % v/v 0.1 M phosphate buffer (pH 4.5), 30 % acetonitrile, and 2.3 g sodium dodecyl sulphate/liter at a flow rate of 1 ml /min and a temperature of 40°C.
  • the sample volume was 10 ⁇ l and detection was carried out using a UV-detector running at 260 nm.
  • the membranes used were regenerated cellulose acetate dialysis tubing with varying MW cut-off and vinyl and polyethylene membranes with varying thickness.
  • Table I shows a comparison of the release profile of nicotine for a commercial non-woven snuff-bag, and a piece of filter paper used as reference in the experiments. The measurements were performed as described above, and the results are the mean of 2 single runs. Table I. Comparison of the nicotine release profile for a commercial non-woven filter and a reference paper filter Filter type Nicotine released (mg/ml) 15 sec. 30 min. 60 min. 90 min. Reference paper filter 11.5 64.4 92.0 202.4 Commercial non-woven filter 9.4 65.8 90.1 205.5
  • Hydrophobic membranes e.g. vinyl and polyethylene membranes
  • the slower profile is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water rather than through aqueous pores.
  • Figure 1 shows that the release of nicotine over a hydrophilic membrane made of regenerated cellulose acetate dialysis tubing is high and close to the nicotine release over the reference filter paper.
  • Figure 1 also shows that the physical properties, i.e. the molecular weight cut-off and thickness of the hydrophilic membrane, affect the permeability of nicotine as stated below.
  • a membrane with a relatively small molecular weight cut-off tends to have a sigmoid release profile for nicotine.
  • a considerable lag time is expected before the nicotine starts to permeate the membrane, even though the size of a nicotine molecule is significantly smaller than the molecular weight cut-off of 3,500.
  • a membrane with a higher molecular weight cut-off e.g. a molecular weight cut-off of 13,000, seems to have a release profile for nicotine that is very close to the release profile for nicotine of the reference filter paper.
  • This difference may be due to a much lower aqueous mobility of nicotine in the membrane with a molecular weight cut-off of 3,500, compared to the membrane with a molecular weight cut-off of 13,000.
  • Figure 1 also shows that when the thickness of a membrane increases, then the flux of nicotine through the membrane decreases.
  • Example 1 shows that it is possible to design a polymeric membrane which gives rise to a release profile of nicotine from moist tobacco through the membrane very similar to the release profile through a commercial non-woven snuff-bag, i.e. with respect to the shape of the profile and the individual release data (time, percentage released). Especially, it seems that a hydrophilic membrane material is suitable. Furthermore, the release profile is dependent of the molecular weight cut-off of the membrane, the thickness of the membrane and of the membrane material itself.
  • Example 1 also shows that some hydrophobic membranes, e.g. vinyl and polyethylene membranes, have a slower nicotine release profile compared to the hydrophilic membranes.
  • hydrophobic membranes e.g. vinyl and polyethylene membranes
  • membranes which enable a specific release of nicotine, i.e. it is possible to design membranes having desired release characteristics e.g. a quick or a slow release of nicotine dependent on the purpose of the composition.
  • desired release characteristics e.g. a quick or a slow release of nicotine dependent on the purpose of the composition.
  • the specific features of a membrane or a membrane material can be used to design a controlled and well-defined release profile for the release of nicotine from a composition according to the invention.
  • Membranes made from regenerated cellulose acetate dialysis tubing with varying thickness and molecular weight cut-off were tested for their selectivity in transporting nicotine across the membrane, while unwanted and potentially harmful substances are retained in the tobacco.
  • the Impurity Index - lPl - was introduced as a measure for the selective release of nicotine.
  • the IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. All measurements are performed in the receiver chamber, i.e. after permeation through the membrane in question. The IPI is measured 3, 30 and 90 min after start of the experiment, cf. above. In those cases where any additionally substances are added to the tobacco composition such as, e.g., sweeteners, flavors, detergents, buffers, etc. the peak heights of these are normally not included when calculating the sum of peak height as described above.
  • IPI Impurity index
  • the decrease in lPl is not merely a result of a decrease in the overall release rate. Accordingly, the release profiles relating to nicotine and employing cellulose membranes with a molecular weight cut-off of 13,000 are only a few percent lower than the release profile for the reference filter paper. Thus, employment of such membranes enables a release, which permits release of wanted substances (i.e. nicotine) while retaining unwanted substances.
  • Example 2 shows that no significant loss in membrane selectivity is observed as the membrane thickness is being decreased. Therefore, further studies to investigate the relationship between membrane thickness, molecular weight cut-off of the membrane and amount of nicotine transferred over the membrane were performed by analyzing selected data from Example 1.
  • the maximum slope for each release profile has been deduced.
  • the maximum slope i.e. percentage nicotine release per time unit, dR/dt represents the maximum flux of nicotine through the membranes (see Table 4).
  • Figure 3 shows a plot of the maximum flux as a function of membrane thickness for the cellulose membrane with a molecular weight cut-off of 13,000.
  • the Figure shows that the flux of nicotine through a membrane is approaching the flux through a reference filter paper, which practically has no barrier to the nicotine diffusion, at a membrane thickness of about 10 ⁇ m.
  • a hydrophilic membrane with a molecular cut off about 13,000 does not seem to give rise to any boundary layer/membrane effects or any major diffusion limitations for nicotine.
  • a thickness of approx.10 ⁇ m will give a release profile equal to the original commercially available non-woven moist snuff pouches.
  • the sensation of taking up nicotine into the blood stream from the oral cavity was scored using a scale rating from zero to five, with zero indicating no feeling and 5 indicating a very strong feeling of uptake, leading to dizziness and nausea.
  • the results show that the effect of nicotine uptake from the novel snuff composition is slightly delayed compared to the sensation of nicotine uptake from the commercially available bag snuff.
  • the volunteers feel an effect rated 5 after 8 to 10 minutes.
  • the volunteers feel the maximum effect between 12 to 16 minutes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Cosmetics (AREA)

Abstract

A novel composition for the use as snuff in the oral cavity, the composition comprising tobacco and/or a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble. A novel composition enables a selective release of e.g. nicotine while it at the same time reduces the release of substances, which normally lead to unwanted side effects. The novel compositions may be used as a healthier alternative to snuff and other tobacco products such as, e.g., cigarettes, cigars and pipe. Methods for giving up smoking, reducing nicotine craving, reducing side effects normally related to smoking and snuffing of tobacco as welt a method for the preparation of a composition according to the invention.

Description

    FIELD OF THE INVENTION
  • The present invention relates to a novel composition for the use as snuff in the oral cavity, the composition comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble. A novel composition enables a selective release of e.g. nicotine while it at the same time reduces the release of substances, which normally lead to unwanted side effects. The novel compositions may be used as a healthier alternative to snuff and other tobacco products such as, e.g., cigarettes, cigars and pipe.
  • The invention also relates to methods for giving up smoking, reducing nicotine craving, reducing side effects normally related to smoking and snuffing of tobacco as well to a method for the preparation of a composition according to the invention.
  • BACKGROUND OF THE INVENTION
  • The use of tobacco is deeply rooted in a large part of the world population. In the Scandinavian countries and in particular Sweden the use of moist snuff (snus) is very common as an alternative to smoking. Snuff is fermented and milled/grinded tobacco with a relatively large water content (40 - 60 % w/w), normally to be used under the front upper lip of a human being.
  • Tobacco itself varies somewhat in nicotine content due to its natural origin. To adjust the nicotine release in moist snuff, various buffer systems may be added, e.g. carbonates. The moist snuff is either packed loosely, as bulk in a box or as single doses in small non-woven bags. A number of the filled and sealed bags are then packed in a box.
  • The moist snuff as a single dose has become popular due to the ease of use compared to the bulk product. The popularity of moist snuff is most probably due to its pharmacological nicotine absorption profile. The dose of nicotine and speed of absorption is approximately 10 ng per ml over 10 minutes. Plasma nicotine concentrations rapidly increase within the first few minutes of the use of snuff and reach levels comparable to those obtained from smoking cigarettes within 30 min of use. Measurements of plasma nicotine concentrations after a single day of moist snuff consumption also yielded levels similar to cigarette use.
  • The kinetics is slightly slower compared to the kinetics when smoking tobacco, such as e.g. cigarettes and cigars; however, the overall amount of nicotine absorbed is higher when snuff is employed.
  • Like the daily use of cigarettes, cigar, pipe and other smoke products, a daily use of snuff burdens the users body with a number of harmful compounds endogenous to tobacco.
  • The disadvantage of snuff is the vast number of compounds, more or less harmful to the body, e.g. different tobacco-specific nitrosamines, which are compounds known to cause different diseases such as, e.g., gastro-intestinal disorders and cancer.
  • Various tobacco products and/or devices for tobacco products wherein the user achieves the desired effect from nicotine, but at the same time avoids the harmful substances released from the tobacco are already known from the literature.
  • In US 4,848,376 an inhalation device is presented where tobacco is used more or less as in a cigarette and the nicotine is liberated due to elevated temperatures, though below the combustion temperature of tobacco.
  • US 4,141,369 describes a method of inhaling the nicotine from tobacco without combustion of the tobacco.
  • Another way of avoiding the harmful substances contained in tobacco is to substitute tobacco with nicotine.
  • In US 4,655,231 an artificial dry snuff containing nicotine is suggested. The snuff, composed of pure nicotine salts and excipients e.g. powdered organic sugars, is intended for the administration to the nasal membranes. This is a medicinal nasal composition not based on natural tobacco.
  • Various devices have also be constructed in order to deliver nicotine from a tobacco composition placed in the oral cavity:
  • US 5,346,734 describes a perforated latex oral pouch for loose, moist snuff, the pouch serving as a barrier to avoid direct physical contact between the tobacco product and the gum. The pouch has to be filled by the user, cut to fit the mouth cavity of the user and is re-usable.
  • US 6,162,516 describes a shield, which also has to be filled with snuff by the user, the shield acting as a barrier to reduce tobacco contact with the sensitive inner cheek lining and gum surfaces while using snuff.
  • Both US 5,346,734 and US 6,162,516 do provide the user with a protective device to avoid a direct contact of the tobacco fibers in the snuff with the oral tissues, but no means have been taken in order to avoid or reduce the release of potentially harmful and unwanted substances. Thus, potentially harmful and unwanted substances are still released from the tobacco into the oral cavity.
  • None of the above documents has solved the problems concerning eliminating or delaying the release in the oral cavity of unwanted and harmful substances when using a tobacco containing product as a snuff. Thus, there is still a need for the development of tobacco containing products, which do not deliver unwanted and harmful substances to the body after application.
  • DISCLOSURE OF THE INVENTION
  • Accordingly, the present invention provides a composition wherein the release of nicotine from snuff can be designed freely, even though the release of unwanted and harmful substances from the tobacco is dramatically reduced.
  • Thus, the present invention provides a composition for use in the oral cavity comprising tobacco and/or tobacco in combination with a tobacco substitute encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble.
  • The gist of the invention is the employment of a membrane material which makes it possible to deliver nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof in a predetermined manner and - at the same time - has the properties of withholding the substances which are unwanted to such a degree that the side-effects normally observed in connection with the use of snuff in the oral cavity are dramatically reduced.
  • Tobacco
  • The tobacco used in the novel snuff composition according to the invention may be natural tobacco leaves in order to preserve the authentic taste and feeling of tobacco. The tobacco plant belongs to the family Solanaceae and the genus Nicotiana. More than 60 tobacco species exists, the most commonly used in smoking or snuffing tobacco products being Nicotiana tabacum and Nicotiana rustica. To manufacture moist snuff, the tobacco, which typically has a content of from about 1% to 8% nicotine, is dried, milled and mixed with a fermentative solution. The mixture is then fermented, typically for 5 days to 4 weeks at elevated temperature. After this the tobacco mass is mixed with a suitable buffer, such as e.g. carbonate, so a pH of about 6 to 8 for the moist snuff mixture is obtained, to enable and enhance the release of nicotine or a derivative thereof from the tobacco. The water content in the final product may lie in the range from about 10 % to about 60 %.
  • To the moist snuff additional compounds may be added, such as e.g. sweeteners, aroma substances and other taste additives, detergents and preservative, release modifying agents, and other liquids such as oil, organic solvents and herbal extracts.
  • In another embodiment of the invention the natural fermented tobacco may be partly substituted with a tobacco substitute, such as, e.g., nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate. To maintain the same feeling of having the moist snuff product in the oral cavity, some additional filler may be added, such as, e.g., non-digestible fibers.
  • Whether natural tobacco and/or tobacco in combination with a tobacco substitute are used for the novel snuff composition, the tobacco and/or tobacco substitute may preferably have a content of nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof, from about 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15% w/w, from about 0.1% w/w to about 10% w/w, from about 0.1% w/w to about 9% w/w or from about 0.1% w/w to about 8% w/w.
  • Membrane material
  • According to the invention, the tobacco and/or tobacco substitute is enclosed in a membrane material. The membrane material may comprise one or more membranes. In the present context the term "membrane" describes a thin polymeric film having natural pores and acting as a selective permeability barrier. The term does not include papermade material or polymeric materials in which not-naturally occurring openings have been made.
  • At least one of the membranes may be water-insoluble to prevent spreading of the snuff in the oral cavity, and to maintain the beneficial properties of the selective membrane material during use, with respect to the withholding of unwanted substances.
  • At least one of the membranes may be water permeable in order to allow water to diffuse into the encapsulated tobacco and/or tobacco substitute and to allow e.g. nicotine to diffuse through the polymeric membrane material and thus becoming available for absorption.
  • The membranes may have a predominantly hydrophilic or hydrophobic nature. The hydrophilic or hydrophobic nature of the membrane has an effect on the release of substances such as, e.g., nicotine through the membrane, since the flow of substances through the membrane is dependent on the ability of the membrane to hydrate, e.g. create hydro-channels through the membrane. These hydro-channels are a prerequisite for molecular transport when dry polymeric membranes are used. In general, the flow of hydrophilic substances through a hydrophobic membrane is slower compared to a hydrophilic membrane. This is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water.
  • One or more of the membranes used for making the composition may be a synthetic or semi-synthetic membrane. Below is given some examples of natural, synthetic and semi-synthetic hydrophilic and hydrophobic membranes, which may be used in a novel snuff composition according to the invention.
  • Examples of membranes are membranes made of cellulose acetate and derivates thereof, carboxymethyl cellulose membranes, polycellulose ester membranes, other cellulose derivatives such as, e.g., ethylcellulose, propylcellulose, polyethylene membranes, polypropylene membranes, polystyrene membranes, polyvinyl chloride membranes, polyvinyl acetate membranes, membranes made of polymers of methacrylates and acrylates, natural rubber membranes, polycarbonate membranes, polyethylene terephthalate membranes, polyester membranes, polyamide membranes and nylon membranes.
  • At least the outer membrane in the membrane material enclosing the tobacco and/or tobacco substitute may be made from a biocompatible and physiologically acceptable polymeric material, since the novel snuff composition has to be placed close to or in contact with the mucous membrane in the oral cavity during use.
  • Furthermore, at least one of the membranes in a membrane material may be surface treated with e.g. polycarbophils to obtain a bioadhesiveness of the novel snuff composition in the oral cavity.
  • The molecular weight cut off of the membrane material used in the novel snuff composition may be varied to obtain a desired release of nicotine and other substances through the membrane material. The molecular weight cut-off of a membrane is defined as the molecular weight of the smallest molecule of which 90 % will be prevented from permeating the membrane. In addition to molecular weight, the exact permeability of a molecule is dependent on the shape, the degree of hydration and the charge of the molecule.
  • At least one of the membranes comprising the membrane material may have a molecular weight cut-off from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500; or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25,000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
  • The release of nicotine and/or other substances through the membrane material is also dependent on the thickness of the membrane materiel. The diffusion process of molecules through the membrane is decreased when the membrane thickness is increased and vice versa. Thus, the thickness of the membrane material may be varied in respect of obtaining a desired release of nicotine and other substances through the membrane material.
  • The lower limit for the membrane material thickness is determined by what is possible from a practical point of view, and the upper value is restricted by what will allow a comfortable fit of the novel snuff composition in the oral cavity of the user.
  • Accordingly, at least one of the membranes comprising the membrane material may have a thickness of from 2 to about 200 µm such as, e.g., from about 5 to about 100 µm, from about 7.5 to about 50 µm, from about 7.5 to about 40 µm, from about 7.5 to about 35 µm, from about 7.5 to about 30 µm or from about 7.5 to about 25 µm.
  • Release profiles
  • To obtain an effect from the novel snuff composition, nicotine or a nicotine derivative, analog, salt, solvate or a mixture thereof, selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate, has to be released from the composition.
  • The release profile may be designed with respect to the rate and amount of nicotine and unwanted substances released by the membrane.
  • The release of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from a novel snuff composition may be designed to be released in a sufficient amount and/or a sufficient rate to enable a desired effect and on the other hand be designed to retain substances, which normally give rise to side-effects, such as, e.g., nitrosamines, and/or to release such substances in a substantially low amount and/or at a substantially slow rate.
  • As a measure of the selective release of nicotine or a derivative, analog, salt, solvate or a mixture thereof, the Impurity Index- IPI - is introduced.
  • The IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm as described in Example 2, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. In other words, a low IPI reflects that a large amount of nicotine is released through the membrane compared to the amount of unwanted substances.
  • In a preferred embodiment of the invention the impurity index IPI is at the most 3.0 such as, e.g. at the most 2.75, at the most 2.5, at the most 2.0, at the most 1.75, at the most 1.5, at the most 1.5 or at the most 1.4 when measured after 90 min.
  • In one embodiment of the invention the release profile of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the invention could e.g., be fast and equivalent to the release of nicotine from the commercially available moist snuff, while maintaining a low IPI value, i.e. limiting the release of unwanted substances.
  • Moreover, a composition according to the invention can be designed to release nicotine and/or a derivative, analog, salt, solvate or mixture thereof in a controlled manner such as, e.g., fast (faster than from the reference product employed in the examples herein), relatively fast (i.e. similar or almost similar to the reference product employed in the examples herein), delayed (i.e. with a lag time in which period no nicotine is released followed by a release of nicotine), prolonged or sustained (i.e. a relatively slower release than the reference product to avoid any peak concentration and to obtain a relatively constant plasma concentration of nicotine after application).
  • In another embodiment of the invention the release of nicotine or a derivative, analog, salt, solvate or a mixture thereof, may be delayed compared to the commercially available moist snuff, to mimic the effect of nicotine replacement products such as, e.g., patches.
  • The release of nicotine or a derivative, analog, salt, solvate or a mixture thereof, may be determined by the release test described in Example 1, but other suitable methods for determining the release of nicotine may also be used, i.e. the embodiments of the invention described below referrer to Example 1 without limiting the relevant release tests to the one described in Example 1.
  • The tobacco and/or tobacco in combination with a tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
  • In a further embodiment of the invention the tobacco and/or tobacco substitute composition may be designed so that at the most 25% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described in Example 1 below.
  • In yet another embodiment the tobacco and/or tobacco substitute composition may be designed so that at least about 50% w/w of the total content of nicotine and/or a derivative, analog, salt, solvate or a mixture thereof is released within at the most 120 min when subject to the release test described in Example 1 below.
  • Below follows release profiles for compositions according to the invention. The release profiles are described as %w/w released of total nicotine content as a function of time, measured at 0, 3, 30, 90 and 180 minutes. However, the release profiles according to the invention also includes profiles described by only one or any combination of the values below, i.e. a release profile according to the invention could be defined by e.g. the %w/w release of nicotine at 3 minutes and 90 min, or at 3 and 90 and 180 minutes, or at 90 and 180 minutes or any possible combination of the values shown below.
  • A composition according to the invention is suitable designed to release nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or tobacco in combination with the tobacco substitute with the following characteristics:
    time (min) % w/w released of total nicotine content
    0 from about 0 to about 20 such as, e.g., from about 0 to about 15 or from about 0 to about 10,
    3 from about 0 to about 40 such as, e.g., from about 0 to about 35, from about 0 to about 30, from about 0 to about 25, from about 0 to about 20,
    30 from about 2 to about 100, such as, e.g., from about 2 to about 90, from about 2 to about 80, from about 2 to about 70, from about 2 to about 65, from about 2 to about 60, from about 5 to about 60, from about 5 to about 55, from about 7.5 to about 55 or from about 10 to about 50, op til 100
    90 from about 10 to about 100 such as, e.g., from about 10 to about 95, from about 15 to about 90, from about 20 to about 90, from about 25 to about 85, from about 30 to about 80, from about 35 to about 80 or from about 40 to about 80,
    180 from about 40 to about 100 such as, e.g. from about 45 to about 100, from about 50 to about 100, from about 55 to about 100, from about 60 to about 100, from about 65 to about 100 or from about 70 to about 100,
    and the release is determined as described herein in Example 1.
  • More specifically, a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics:
    time (min) % w/w released of total nicotine content
    0 from about 0 to about 15
    3 from about 1 to about 25
    30 from about 7.5 to about 55
    90 from about 35 to about 80
    180 from about 65 to about 100
    and the release is determined as described herein in Example 1.
  • In a further embodiment, a composition according to the invention releases, nicotine and/or derivative, analog, salt or solvate thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics:
    time (min) % w/w released of total nicotine content
    0 from about 0 to about 10
    3 from about 1 to about 20
    30 from about 10 to about 50
    90 from about 40 to about 90
    180 from about 70 to about 100
    and the release is determined as described herein in Example 1.
  • In a still further embodiment, a composition according to the invention releases nicotine and/or a derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco in combination with a tobacco substitute with the following release profile characteristics:
    time (min) % w/w released of total nicotine content
    0 from about 0 to about 10
    3 from about 1 to about 20
    30 from about 30 to about 50
    90 from about 65 to about 90
    and the release is determined as described herein in Example 1.
  • Design of membrane material
  • As described above, membrane material properties such as hydrophobicity, hydrophilicity, molecular weight cut-off and membrane thickness may be used in designing a desired release profile for nicotine or a derivative, analog, salt, solvate or mixture thereof.
  • In the following are given some examples of how membrane materials can be designed. The examples are for illustrative purposes and are not intended to limit the invention in any way.
  • A multi-layer membrane is e.g. designed to contain one membrane material being hydrophilic and a second membrane material being lipophilic. Both membrane components are chosen in such a manner that the membrane material has a molecular cut off large enough for the relatively small nicotine molecule to pass through with ease.
  • The amphiphilic nature of nicotine enables it to pass both hydrophilic and hydrophobic materials while a majority of both hydrophilic and lipophilic unwanted and harmful substances are excluded from permeation through the membrane material. Many other combinations of different types of membranes are of course possible and based on the disclosure herein a skilled person will know how to chose different membranes in order to obtain a suitable release.
  • Another example of a composition according to the invention is a composition wherein the membrane material is a bi-layer membrane with one membrane being preferentially hydrophilic and one membrane being predominantly hydrophobic. Both membranes possess high permeability to nicotine while maintaining low aqueous pore diffusion. The release profile of nicotine could either be identical to the release profile of original snuff or it could be designed to have a prolonged or sustained release. The unwanted and harmful substances from the tobacco should substantially be maintained inside the membrane.
  • Shape and size of a composition according to the invention
  • A composition according to the invention may attain all possible sizes and shapes, such as, e.g. round, circular, oblong, elliptical, square, rectangular or trapezoidal. The shape and/or size chosen may be such as to allow a comfortable fit in the oral cavity.
  • The location in the oral cavity of a composition according to the invention may be centered or to the sides under the upper front lip, centered or to the sides under the lower front lip, under the tongue or in the cheeks.
  • Other aspects of the invention
  • In other aspects, the invention also relates to use of a composition according to the invention as a smoke substitute and it can be used by persons who suffer from nicotine craving or who want to give up or reduce smoking. In such cases, the content of tobacco and/or a tobacco substitute is adjusted to the individual purposes and it is possible to design a kit comprising compositions according to the invention with different concentrations of tobacco and/or a tobacco substitute. Such compositions in a kit could e.g. contain compositions with a decreasing content of tobacco or nicotine.
  • In a still further aspect of the invention it relates to a method for preparing a composition according to the invention.
  • The details and description relating to the composition aspects apply mutatis mutandi to the other aspects of the invention.
  • BRIEF DESCRIPTION OF THE DRAWINGS
    • Figure 1 shows the release profile from moist tobacco using side-by-side diffusion cells equipped with specific membranes having different physical properties.
    • Figure 2 shows the impurity index (IPI) for various hydrophilic membranes with different thickness and molecular weight cut-offs. The reference is filter paper.
    • Figure 3 shows the maximum flux of nicotine as a function of membranes thickness for a hydrophilic membrane with a molecular weight cut-off of 13,000. The reference flux illustrates the flux through filter paper.
  • The following examples are intended to illustrate the invention without limiting it thereto.
  • EXAMPLES Example 1 Diffusion profiles of hydrophobic membranes and hydrophilic membranes with different physical properties
  • Membranes made of regenerated cellulose acetate dialysis tubing with varying MW cut-off together with vinyl and polyethylene membranes with various thicknesses were tested with respect to the diffusion profiles over the membranes of nicotine released from tobacco.
  • Diffusion chamber experiment
  • In a side-by-side diffusion chamber separated by a membrane, 1 g of snuff tobacco (SVENSKT SNUS, GOTHIATEK, General) was placed in an aqueous PBS (phosphate buffered saline according to Ph. Eur.) with a pH of 6.6 on the donor side of the membrane in the diffusion chamber. In the receiver chamber PBS with a pH of 6.6 was placed. The cells of the diffusion chamber were kept at a temperature of 37°C ± 0.5°C by attachment to a water bath. The temperature control was made in order to simulate the environment of the oral cavity.
  • Diffusion profiles were constructed by sampling from the receiver chamber at 0, 3, 30, 60, 90, 120, (110 min for the polyethylene membrane) and 180 min after the start of the diffusion experiment. The concentration of nicotine in the receiver chamber was measured by HPLC, using a C-18, 5µ, 4.5 mm x 15 cm column, employing a mobile phase consisting of 70 % v/v 0.1 M phosphate buffer (pH 4.5), 30 % acetonitrile, and 2.3 g sodium dodecyl sulphate/liter at a flow rate of 1 ml /min and a temperature of 40°C. The sample volume was 10 µl and detection was carried out using a UV-detector running at 260 nm.
  • The membranes used were regenerated cellulose acetate dialysis tubing with varying MW cut-off and vinyl and polyethylene membranes with varying thickness.
  • As a reference a piece of filter paper with a average pore size of 8.8 µm, mimicking the commercially used non-woven bag for snuff, was used.
  • Reference filter paper
  • Table I shows a comparison of the release profile of nicotine for a commercial non-woven snuff-bag, and a piece of filter paper used as reference in the experiments. The measurements were performed as described above, and the results are the mean of 2 single runs. Table I. Comparison of the nicotine release profile for a commercial non-woven filter and a reference paper filter
    Filter type Nicotine released (mg/ml)
    15 sec. 30 min. 60 min. 90 min.
    Reference paper filter 11.5 64.4 92.0 202.4
    Commercial non-woven filter 9.4 65.8 90.1 205.5
  • The results from Table I show that the reference filter paper exerts no barrier function to the transport of nicotine.
  • Hydrophobic membranes
  • Hydrophobic membranes, e.g. vinyl and polyethylene membranes, show a slower nicotine release profile compared to hydrophilic membranes (see Figure 1). The slower profile is probably due to less swelling of the hydrophobic membrane pores, i.e. in the hydrophobic membranes nicotine diffusion occurs through well-organized polymeric material and hydrophobic organized water rather than through aqueous pores.
  • In Table 2 below are given the results from the above-mentioned experiment.
  • Hydrophilic membranes
  • Figure 1 shows that the release of nicotine over a hydrophilic membrane made of regenerated cellulose acetate dialysis tubing is high and close to the nicotine release over the reference filter paper. Figure 1 also shows that the physical properties, i.e. the molecular weight cut-off and thickness of the hydrophilic membrane, affect the permeability of nicotine as stated below.
  • A membrane with a relatively small molecular weight cut-off, e.g. a molecular weight cut-off of 3,500, tends to have a sigmoid release profile for nicotine. In other words, a considerable lag time is expected before the nicotine starts to permeate the membrane, even though the size of a nicotine molecule is significantly smaller than the molecular weight cut-off of 3,500.
  • However, a membrane with a higher molecular weight cut-off, e.g. a molecular weight cut-off of 13,000, seems to have a release profile for nicotine that is very close to the release profile for nicotine of the reference filter paper.
  • This difference may be due to a much lower aqueous mobility of nicotine in the membrane with a molecular weight cut-off of 3,500, compared to the membrane with a molecular weight cut-off of 13,000.
  • Figure 1 also shows that when the thickness of a membrane increases, then the flux of nicotine through the membrane decreases.
  • Example 1 shows that it is possible to design a polymeric membrane which gives rise to a release profile of nicotine from moist tobacco through the membrane very similar to the release profile through a commercial non-woven snuff-bag, i.e. with respect to the shape of the profile and the individual release data (time, percentage released). Especially, it seems that a hydrophilic membrane material is suitable. Furthermore, the release profile is dependent of the molecular weight cut-off of the membrane, the thickness of the membrane and of the membrane material itself.
  • Example 1 also shows that some hydrophobic membranes, e.g. vinyl and polyethylene membranes, have a slower nicotine release profile compared to the hydrophilic membranes.
  • All these observations make it possible to design membranes, which enable a specific release of nicotine, i.e. it is possible to design membranes having desired release characteristics e.g. a quick or a slow release of nicotine dependent on the purpose of the composition. In other words, the specific features of a membrane or a membrane material can be used to design a controlled and well-defined release profile for the release of nicotine from a composition according to the invention. Table 2: Release of nicotine from membranes of various kinds, thicknesses and pore sizes
    Membrane Release of nicotine (%)
    0 min 3 min 30 min 90 min 120 min 180 min
    Reference filter (original) 4.7 18.7 46.5 80.8 88.8 100
    23 µm cellulose membrane 13,000 MW cut-off 2.4 4.1 36.6 73.2 83.7 100
    46 µm cellulose membrane 13,000 MW cut-off 1.6 2.4 33.3 69.1 79.2 100
    93 µm cellulose membrane 13,000 MW cut-off 0 0 17.2 43.9 49.0 69.7
    25 µm cellulose membrane 3,500 MW cut-off 0.9 2.7 11.6 67.0 75.9 100
    50 µm cellulose membrane 3,500 MW cut-off 0.9 1.7 4.3 49.9 56.8 80.0
    20 µm Polyetylene 0 0 3.0 -- 22* --
    * Measured after 110 min
  • Example 2 Selectivity of the release of tobacco components over membranes with different properties
  • Membranes made from regenerated cellulose acetate dialysis tubing with varying thickness and molecular weight cut-off were tested for their selectivity in transporting nicotine across the membrane, while unwanted and potentially harmful substances are retained in the tobacco.
  • To examine the selectivity of the membranes, an experimental set-up as described in Example I was used.
  • As membranes were used regenerated cellulose acetate with molecular weight cut-off of 3,500 and a thickness of 25.2 µm or a molecular weight cut-off of 13,000 and a thickness of 23.2 µm or 46.4 µm. Samples were withdrawn at 3, 30 and 90 minutes after the start of the experiment and an UV spectrum from 200 nm to 900 nm was recorded for each sample.
  • As previous described, the Impurity Index - lPl - was introduced as a measure for the selective release of nicotine. The IPI is calculated from the UV-spectra recorded from 200 nm to 900 nm, and is defined as the ratio of the sum of peak heights other than that of nicotine (i.e. thus including unwanted and harmful substances) to the peak height of nicotine. All measurements are performed in the receiver chamber, i.e. after permeation through the membrane in question. The IPI is measured 3, 30 and 90 min after start of the experiment, cf. above. In those cases where any additionally substances are added to the tobacco composition such as, e.g., sweeteners, flavors, detergents, buffers, etc. the peak heights of these are normally not included when calculating the sum of peak height as described above.
  • As mentioned before, a low IPI reflects that a large amount of nicotine is released through the membrane compared to the amount of unwanted substances. Table 3 shows IPI values calculated for the reference filter paper and for hydrophilic membranes with different molecular weight cut-off and different thickness. Table 3: Impurity index (IPI) calculated for the reference filter paper membrane and hydrophilic regenerated cellulose acetate membranes with different physical properties
    Time Impurity index (IPI)
    (min) Membrane 1 Membrane 2 Membrane 3 Reference
    Thick:   25.2 µm Thick:   23.2 µm Thick   46.4 µm
    MWCO   3,500 MWCO   13,000 MWCO  13,000
    3 0.9 0.75 1.05 1.64
    30 1.17 1.24 1.17 2.91
    90 1.26 1.35 1.25 3.35
    IPI = Σ Peak height other substances/ Σ Peak height nicotine
    MWCO = molecular weight cut-off
  • The results in Table 3 show that the amount of unwanted substances can be decreased almost three times when a cellulose membrane with a thickness and a molecular weight cut-off in the range described in Table 3 is used compared to the reference filter paper.
  • As shown in Figure 1, the decrease in lPl is not merely a result of a decrease in the overall release rate. Accordingly, the release profiles relating to nicotine and employing cellulose membranes with a molecular weight cut-off of 13,000 are only a few percent lower than the release profile for the reference filter paper. Thus, employment of such membranes enables a release, which permits release of wanted substances (i.e. nicotine) while retaining unwanted substances.
  • The results from Table 3 and Fig. 1 indicate that the release rate of unwanted substances increases with decreasing membrane thickness. However, it is important to note that such an increase seems to correspond to the increase in the release rate of nicotine, i.e., a decrease in membrane thickness will not lead to a more pronounced release of unwanted substances. In other words, the IPI value is not increasing when the thickness of the membrane with a molecular weight cut-off of 13,000 is decreased from 46.4 µm to 23.2 µm.
  • Example 3 Optimization of membrane properties with respect to molecular weight cut-off, thickness and low IPI values
  • Example 2 shows that no significant loss in membrane selectivity is observed as the membrane thickness is being decreased. Therefore, further studies to investigate the relationship between membrane thickness, molecular weight cut-off of the membrane and amount of nicotine transferred over the membrane were performed by analyzing selected data from Example 1.
  • From Figure 1, the maximum slope for each release profile has been deduced. The maximum slope, i.e. percentage nicotine release per time unit, dR/dt represents the maximum flux of nicotine through the membranes (see Table 4).
    Figure imgb0001
  • Figure 3 shows a plot of the maximum flux as a function of membrane thickness for the cellulose membrane with a molecular weight cut-off of 13,000. The Figure shows that the flux of nicotine through a membrane is approaching the flux through a reference filter paper, which practically has no barrier to the nicotine diffusion, at a membrane thickness of about 10 µm.
  • A hydrophilic membrane with a molecular cut off about 13,000 does not seem to give rise to any boundary layer/membrane effects or any major diffusion limitations for nicotine. A thickness of approx.10 µm will give a release profile equal to the original commercially available non-woven moist snuff pouches.
  • Example 4 Studies of nicotine uptake in humans from a novel snuff composition
  • The sensation of nicotine uptake in humans when using commercially available bag-snuff compared to a novel snuff composition according to the invention was studied.
  • In the study, the uptake of nicotine from 1 g of snuff (SVENSKT SNUS, GOTHIATEK, General) in original non-woven pouches was compared to the uptake of nicotine from 1 g of snuff contained in a regenerated cellulose membrane with a molecular weight cut-off of 13,000 and a thickness of 23.2 µm.
  • The study was performed with human volunteers who were not snuff users.
  • Each individual placed a portion of snuff under the upper lip, and they scored their observations concerning the sensation of taking up nicotine into the blood stream within certain time intervals.
  • The sensation of taking up nicotine into the blood stream from the oral cavity was scored using a scale rating from zero to five, with zero indicating no feeling and 5 indicating a very strong feeling of uptake, leading to dizziness and nausea.
  • The results from the study of nicotine uptake are shown in Table 5.
    Figure imgb0002
  • It is evident from the results shown in Table 5, that the novel snuff composition gives rise to a nicotine effect in the volunteers. Four minutes after the commercially available bag snuff or the novel snuff composition was placed in the oral cavity, two of the volunteers felt a nicotine effect, which they gave a scoring of one. One of the volunteers felt an one-degree higher effect from the commercially available bag snuff compared to the novel snuff composition
  • The results also show that the effect of nicotine uptake from the novel snuff composition is slightly delayed compared to the sensation of nicotine uptake from the commercially available bag snuff. When using the commercially available bag snuff, the volunteers feel an effect rated 5 after 8 to 10 minutes. When using the novel snuff composition the volunteers feel the maximum effect between 12 to 16 minutes.

Claims (39)

  1. A composition for use in the oral cavity comprising a material selected from the group consisting of tobacco and tobacco in combination with a tobacco substitute, the material being encapsulated in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble, and wherein the impurity index of the composition - when determined as described herein - is at the most 3.0 such as, e.g., at the most 2.75, at the most 2.5, at the most 2.0, at the most 1.75, at the most 1.5, at the most 1.5 or at the most 1.4 when measured after 90 min.
  2. A composition according to claim 1 for use as snuff.
  3. A composition according to claim 1 or 2, wherein the composition is not in the form of a chewing gum.
  4. A composition according to any of the preceding claims, wherein at least one membrane is a synthetic or semi-synthetic membrane.
  5. A composition according to any of the preceding claims, wherein at least one membrane is made from natural rubber.
  6. A composition according to any of the preceding claims, wherein at least one membrane is a biocompatible membrane.
  7. A composition according to any of the preceding claims, wherein the membrane is of a polymeric material such as one selected from the group consisting of cellulose acetate and derivates thereof, carboxymethyl cellulose, polycellulose esters, other cellulose derivatives such as, e.g., ethylcellulose, propylcellulose, polyethylene, polypropylene, polystyrene, polyvinyl chloride, polyvinyl acetate, polymers of methacrylates and acrylates, natural rubber, polycarbonates, polyethylene terephthalate, polyesters, polyamides and nylon.
  8. A composition according to any of the preceding claims, wherein at least one of the membranes has predominantly hydrophilic character.
  9. A composition according to any of the preceding claims, wherein at least one of the membranes has predominantly hydrophobic character.
  10. A composition according to any of the preceding claims, wherein nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof is released from the tobacco or the tobacco substitute.
  11. A composition according to claim 10, wherein the release is a controlled release.
  12. A composition according to claim 10 or 11, wherein the nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is selected from the group consisting of nor-nicotine, lobeline, methylanabasine, anabasine, nicotine hydrochloride, nicotine dihydrochloride, nicotine sulphate, nicotine monotartrate, nicotine bitartrate, nicotine salicylate or nicotine zinc chloride monohydrate.
  13. A composition according to any of the preceding claims, which i) is designed to release nicotine and/or a nicotine derivative, analog, salt, solvate or a mixture thereof in a sufficient amount and/or at a sufficient rate to enable a desired effect and ii) is designed to retain substances, which normally give rise to side-effects, and/or to release such substances in a substantially low amount and/or at a substantially slow rate.
  14. A composition according to any of the preceding claims, Wherein at least one of the membranes comprising the membrane material has a molecular weight cut-off of from about 500 to about 40,000 such as, e.g., from about 500 to about 5,000, from about 800 to about 4,000, from about 1,000 to about 3,500, or from about 2,000 to about 40,000, from about 3,000 to about 30,000, from about 5,000 to about 25.000, from about 7,500 to about 20,000 or from about 10,000 to about 20,000.
  15. A composition according to any of the preceding claims, wherein at least one of the membranes comprising the membrane material has a thickness of from about 2 to about 200 µm such as, e.g., from about 5 to about 100 µm, from about 7.5 to about 50 µm, from about 7.5 to about 40 µm, from about 7.5 to about 35 µm, from about 7.5 to about 30 µm or from about 7.5 to about 25 µm.
  16. A composition according to any of the preceding claims, wherein at least about 50% w/w of the total content of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described herein.
  17. A composition according to any of claims 1-15, wherein at the most 25% w/w of the total content of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is released within at the most 60 min when subject to the release test described herein.
  18. A composition according to any of claims 1-15 or 17, wherein at least about 50% w/w of the total content of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof Is released within at the most 120 min when subject to the release test described herein.
  19. A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 20 such as, e.g., from about 0 to about 15 or from about 0 to about 10 3 from about 0.5 to about 40 such as e.g., from about 0.5 to about 35, from about 0.5 to about 30, from about 1 to about 25 or from about 1 to about 20 30 from about 2 to about 65 such as, e.g., from about 2 to about 60, from about 5 to about 60, from about 5 to about 55, from about 7.5 to about 55 or from about 10 to about 50 90 from about 10 to about 100 such as, e.g., from about 10 to about 95, from about 15 to about 90. from about 20 to about 90, from about 25 to about 85, from about 30 to about 80, from about 35 to about 80 or from about 40 to about 80 180 from about 40 to about 100 such as, e.g., from about 45 to about 100, from about 50 to about 100, from about 55 to about 100, from about 60 to about 100, from about 65 to about 100 or from about 70 to about 100
    and the release is determined as described herein.
  20. A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 15 3 from about 1 to about 25 30 from about 7.5 to about 55 90 from about 35 to about 80 180 from about 65 to about 100
    and the release is determined as described herein.
  21. A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 10 to about 50 90 from about 40 to about 90 180 from about 70 to about 100
    and the release is determined as described herein.
  22. A composition according to any of the preceding claims, wherein the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from the tobacco or the tobacco substitute has the following characteristics: time (min) % w/w released of total nicotine content 0 from about 0 to about 10 3 from about 1 to about 20 30 from about 30 to about 50 90 from about 65 to about 90
    and the release is determined as described herein in.
  23. A composition according to any of the preceding claims wherein the tobacco is processed from the leafs of the plant family Solanaceae and the genus Nicotiana, such as, e.g., Nicotiana tabacum and Nicotiana rustica.
  24. A composition according to any of the preceding claims comprising nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof as claimed in claim 12 together with tobacco in the form of snuff tobacco and/or a suitable filler substance.
  25. A composition according to any of the preceding claims wherein the composition further comprises sweeteners, aromas, taste additives, detergents, pH adjusting substances, preservatives, buffers, release modifying agents and/or fillers.
  26. A composition according to any of the preceding claims wherein the composition further comprises chemical compounds that enables and enhances the release of nicotine from tobacco such as, e.g., pH regulating buffers, e.g. carbonates buffers oil, organic solvents and herbal extracts.
  27. A composition according to any of the preceding claims, wherein the tobacco or tobacco substitute contains nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof in an concentration of about from 0% w/w to about 30% w/w such as, e.g., from about 0.5% w/w to about 25% w/w, from about 0.1% w/w to about 20% w/w, from about 0.1% w/w to about 15% w/w, from about 0.1% w/w to about 10% w/w, from about 0.1% w/w to about 9% w/w or from about 0.1% w/w to about 8% w/w.
  28. A composition according to any of the preceding claims, wherein the membrane material is composed of at least two different kinds of membranes with respect to e.g. thickness, molecular weight cut-off, hydrophilic/hydrophobic nature and water permeability.
  29. A composition according to any of the preceding claims, wherein the composition has a size and/or shape, which is suitable for application under the upper lip of a human.
  30. A composition according to any of the preceding claims containing a mixture of tobacco and a tobacco substitute.
  31. A composition according to any of the preceding claims for use as a smoke substitute.
  32. A composition according to claim 30 or 31 for use in reducing nicotine craving and/or nicotine abstinence.
  33. A method for controlling the release of nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof from tobacco and/or tobacco substitute in the oral cavity, the method comprising encapsulating a material selected from the group consisting of tobacco and tobacco in combination with a tobacco substitute in a membrane material comprising one or more membranes at least one of which being water permeable and water-insoluble so that nicotine and/or nicotine derivative, analog, salt, solvate or a mixture thereof is released in a sufficient amount and/or at a sufficient rate to i) enable a desired effect and ii) retain substances, which normally give rise to side-effects, and/or release such substances in a substantially low amount and/or at a substantially slow rate.
  34. A method for delivering nicotine and/or derivative, analog, salt or solvate thereof to a person in need thereof, the method comprising applying a composition according to any of claims 1-32 to the oral cavity.
  35. A method for giving up smoking, the method comprising applying a composition according to any of claims 1-32 to the oral cavity.
  36. Use of a composition according to any of claims 1-32 in the manufacture of a medicament for reducing nicotine craving, by applying said composition a composition according to any of claims 1-32 to the oral cavity.
  37. Use of a composition according to any of claims 1-32 in the manufacture of a medicament for reducing side effects related to smoking and/or snuffing tobacco, by applying said composition to the oral cavity.
  38. Use of a composition according to any of claims 1-32 as an alternative to and/or substitute for smoking tobacco.
  39. A method for the preparation of a composition according to any of claims 1-32, the method comprising encapsulating tobacco and/or a tobacco substitute in a membrane material comprising one or more membranes at least one of which being a water permeable and a water-insoluble membrane.
EP02795287A 2001-12-21 2002-12-17 Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity Expired - Lifetime EP1458252B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200101945 2001-12-21
DK200101945 2001-12-21
PCT/EP2002/014853 WO2003053175A2 (en) 2001-12-21 2002-12-17 Tobacco and/or tobacco substitute composition for use as a snuff in the oral cavity

Publications (2)

Publication Number Publication Date
EP1458252A2 EP1458252A2 (en) 2004-09-22
EP1458252B1 true EP1458252B1 (en) 2008-01-23

Family

ID=8160931

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02795287A Expired - Lifetime EP1458252B1 (en) 2001-12-21 2002-12-17 Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity

Country Status (7)

Country Link
US (1) US20050061339A1 (en)
EP (1) EP1458252B1 (en)
AT (1) ATE384450T1 (en)
AU (1) AU2002360097A1 (en)
DE (1) DE60224832T2 (en)
DK (1) DK1458252T3 (en)
WO (1) WO2003053175A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008038556A1 (en) * 2008-06-26 2009-12-31 Eswegee Vliesstoff Gmbh Nonwoven fabric for use as a moisture-permeable, microporous semi-luxury packaging material

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4708795B2 (en) 2002-12-20 2011-06-22 ニコノヴァム エービー Physically and chemically stable nicotine-containing particulate matter
SE0302947D0 (en) 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
JP2008510486A (en) * 2004-08-23 2008-04-10 ユーエス スモークレス タバコ カンパニー Tobacco with diversity
SE0500006L (en) * 2005-01-04 2006-07-05 Peter Stigsson Device for ingesting caffeine in an oral cavity
CN101222861B (en) * 2005-04-29 2010-09-08 菲利普莫里斯生产公司 Tobacco pouch product
US9044049B2 (en) 2005-04-29 2015-06-02 Philip Morris Usa Inc. Tobacco pouch product
US7861728B2 (en) * 2006-02-10 2011-01-04 R.J. Reynolds Tobacco Company Smokeless tobacco composition having an outer and inner pouch
WO2007037962A1 (en) 2005-09-22 2007-04-05 R.J. Reynolds Tobacco Company Smokeless tobacco composition
US20070062549A1 (en) * 2005-09-22 2007-03-22 Holton Darrell E Jr Smokeless tobacco composition
US8685478B2 (en) 2005-11-21 2014-04-01 Philip Morris Usa Inc. Flavor pouch
US7810507B2 (en) 2006-02-10 2010-10-12 R. J. Reynolds Tobacco Company Smokeless tobacco composition
CA2646942C (en) 2006-03-16 2014-07-29 Niconovum Ab Improved snuff composition
WO2008133563A1 (en) * 2007-04-26 2008-11-06 Swedish Match North Europe Ab Moist non-tobacco snuff product
SE529886C2 (en) 2006-04-28 2007-12-18 Swedish Match North Europe Ab A new method for preparing a moisturizing snuff composition that does not contain tobacco
WO2007144687A1 (en) * 2006-06-12 2007-12-21 Philip Morris Products S.A. Non-tobacco pouch product
US7766019B2 (en) * 2006-07-21 2010-08-03 Gp Technologies, Inc. Porous plastic smoking cessation devices
JP5941609B2 (en) * 2006-08-01 2016-06-29 アール・ジェイ・レノルズ・タバコ・カンパニーR.J.Reynolds Tobacco Company Smokeless tobacco
US20080029117A1 (en) * 2006-08-01 2008-02-07 John-Paul Mua Smokeless Tobacco
US20080029116A1 (en) * 2006-08-01 2008-02-07 John Howard Robinson Smokeless tobacco
US20080173317A1 (en) * 2006-08-01 2008-07-24 John Howard Robinson Smokeless tobacco
US9032971B2 (en) 2006-11-15 2015-05-19 Philip Morris Usa Inc. Moist tobacco product and method of making
US8616221B2 (en) 2007-02-28 2013-12-31 Philip Morris Usa Inc. Oral pouch product with flavored wrapper
US20080210249A1 (en) * 2007-03-02 2008-09-04 Luzenberg Robert S Systems, devices and methods for delivering one or more additives to smokeless tobacco
US20090032040A1 (en) * 2007-03-30 2009-02-05 Luzenberg Jr Robert S Porous plastic smokeless tobacco substitutes
US8356606B2 (en) 2007-06-01 2013-01-22 Philip Morris Usa Inc. Production of micronized encapsulated tobacco particles for tobacco flavor delivery from an oral pouch
US8162136B2 (en) * 2007-06-04 2012-04-24 British American Tobacco (Investments) Limited Package for different tobacco products
WO2009004488A2 (en) 2007-06-08 2009-01-08 Philip Morris Products S.A. Capsule clusters for oral consumption
US9888712B2 (en) * 2007-06-08 2018-02-13 Philip Morris Usa Inc. Oral pouch products including a liner and tobacco beads
US8029837B2 (en) * 2007-06-08 2011-10-04 Philip Morris Usa Inc. Chewable pouch for flavored product delivery
WO2009007854A2 (en) * 2007-06-08 2009-01-15 Philip Morris Products S.A. Oral pouch product including soluble dietary fibers
US8950408B2 (en) 2007-07-16 2015-02-10 Philip Morris Usa Inc. Oral pouch product having soft edge
WO2009010875A2 (en) * 2007-07-16 2009-01-22 Philip Morris Products S.A. Oral delivery pouch product with coated seam
WO2009010881A2 (en) 2007-07-16 2009-01-22 Philip Morris Products S.A. Oral pouch products with immobilized flavorant particles
WO2009010884A2 (en) 2007-07-16 2009-01-22 Philip Morris Products S.A. Tobacco-free oral flavor delivery pouch product
US8119173B2 (en) * 2007-07-16 2012-02-21 Philip Morris Usa Inc. Method of flavor encapsulation through the use of a drum coater
US7946295B2 (en) * 2007-07-23 2011-05-24 R. J. Reynolds Tobacco Company Smokeless tobacco composition
EP2179666B1 (en) 2007-07-23 2012-08-29 R.J.Reynolds Tobacco Company Smokeless Tobacco Compositions And Methods For Treating Tobacco For Use Therein
US8061362B2 (en) 2007-07-23 2011-11-22 R. J. Reynolds Tobacco Company Smokeless tobacco composition
US8312886B2 (en) * 2007-08-09 2012-11-20 Philip Morris Usa Inc. Oral tobacco product having a hydrated membrane coating and a high surface area
US9125434B2 (en) * 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
CN107048483A (en) * 2007-10-11 2017-08-18 菲利普莫里斯生产公司 Smokeless tobacco product
JP5193311B2 (en) * 2007-12-21 2013-05-08 スウィーディッシュ・マッチ・ノース・ヨーロップ・アーベー Tobacco or non-tobacco products containing magnesium carbonate
US8469037B2 (en) 2008-02-08 2013-06-25 Philip Morris Usa Inc. Pre-portioned moist product and method of making
US20100018540A1 (en) * 2008-07-28 2010-01-28 David James Doolittle Smokeless tobacco products and processes
US20100018541A1 (en) * 2008-07-28 2010-01-28 Anthony Richard Gerardi Smokeless tobacco products and processes
US20100018882A1 (en) * 2008-07-28 2010-01-28 St Charles Frank K Smokeless tobacco products and processes
US20100018539A1 (en) * 2008-07-28 2010-01-28 Paul Andrew Brinkley Smokeless tobacco products and processes
WO2010031552A1 (en) * 2008-09-17 2010-03-25 Niconovum Ab Process for preparing snuff composition
US20100116281A1 (en) * 2008-11-07 2010-05-13 Jerry Wayne Marshall Tobacco products and processes
US8377215B2 (en) 2008-12-18 2013-02-19 Philip Morris Usa Inc. Moist botanical pouch processing
CN102325472B (en) * 2008-12-19 2015-07-29 美国无烟烟草有限责任公司 The method of tobacco particle and production tobacco particle
US9027567B2 (en) * 2008-12-30 2015-05-12 Philip Morris Usa Inc. Oral pouch product with multi-layered pouch wrapper
US9167835B2 (en) 2008-12-30 2015-10-27 Philip Morris Usa Inc. Dissolvable films impregnated with encapsulated tobacco, tea, coffee, botanicals, and flavors for oral products
US8863755B2 (en) 2009-02-27 2014-10-21 Philip Morris Usa Inc. Controlled flavor release tobacco pouch products and methods of making
US9167847B2 (en) 2009-03-16 2015-10-27 Philip Morris Usa Inc. Production of coated tobacco particles suitable for usage in a smokeless tobacoo product
US9687023B2 (en) * 2009-10-09 2017-06-27 Philip Morris Usa Inc. Moist smokeless tobacco product for oral usage having on a portion of the outer surface at least one friction reducing strip that provides texture during use
US8747562B2 (en) 2009-10-09 2014-06-10 Philip Morris Usa Inc. Tobacco-free pouched product containing flavor beads providing immediate and long lasting flavor release
US8539958B2 (en) 2009-10-13 2013-09-24 Philip Morris Usa Inc. Oral moist smokeless tobacco products with net-structured gel coating and methods of making
EP2529634B1 (en) * 2010-01-28 2018-04-18 Japan Tobacco, Inc. Tobacco product with a hydrophobic wrapping material
US10051884B2 (en) 2010-03-26 2018-08-21 Philip Morris Usa Inc. Controlled release mentholated tobacco beads
EP2558370B1 (en) 2010-04-12 2017-04-05 Altria Client Services LLC Pouch product with improved seal and method
US8241680B2 (en) 2010-06-30 2012-08-14 Rock Creek Pharmaceuticals, Inc. Nutraceutical product containing anatabine and yerba maté
US10028520B2 (en) 2010-09-02 2018-07-24 R.J. Reynolds Tobacco Company Apparatus for manufacturing a smokeless tobacco product incorporating an object, and associated method
US8931493B2 (en) 2010-11-01 2015-01-13 R.J. Reynolds Tobacco Co. Smokeless tobacco products
US9908670B2 (en) 2011-01-31 2018-03-06 American Snuff Company, Llc Container for smokeless tobacco products
SE535587C2 (en) 2011-03-29 2012-10-02 Chill Of Sweden Ab Product containing a free nicotine salt and a non-water-soluble bag
AU2012302257A1 (en) 2011-08-29 2014-03-13 Rcp Development, Inc. Products for anti-inflammation support
US10881132B2 (en) 2011-12-14 2021-01-05 R.J. Reynolds Tobacco Company Smokeless tobacco product comprising effervescent composition
US9420825B2 (en) 2012-02-13 2016-08-23 R.J. Reynolds Tobacco Company Whitened tobacco composition
DK2649888T3 (en) 2012-04-10 2020-04-27 Swedish Match North Europe Ab Smokeless tobacco composition comprising non-tobacco fibers and a process for making them
US20130292279A1 (en) 2012-05-04 2013-11-07 R.J. Reynolds Tobacco Company Transparent moisture barrier coatings for containers
US20130340773A1 (en) 2012-06-22 2013-12-26 R.J. Reynolds Tobacco Company Composite tobacco-containing materials
GB2504495A (en) 2012-07-30 2014-02-05 British American Tobacco Co Fleece for smokeless tobacco pouch
US9386800B2 (en) 2012-09-21 2016-07-12 R.J. Reynolds Tobacco Company Fibrous composite tobacco-containing materials
US9591875B2 (en) 2012-09-21 2017-03-14 R. J. Reynolds Tobacco Company Fibrous composite tobacco-containing materials
GB201220280D0 (en) * 2012-11-12 2012-12-26 British American Tobacco Co Products including capsules, uses and preparation thereof
CN102920013B (en) * 2012-11-19 2015-02-11 湖南中烟工业有限责任公司 Tobacco extractive microcapsule and preparation method thereof
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
US11503853B2 (en) 2013-09-09 2022-11-22 R.J. Reynolds Tobacco Company Smokeless tobacco composition incorporating a botanical material
US10357054B2 (en) 2013-10-16 2019-07-23 R.J. Reynolds Tobacco Company Smokeless tobacco pastille
CN103783648B (en) * 2014-02-21 2015-08-19 安徽中烟工业有限责任公司 The sampling method of the process sample in a kind of beating and double roasting operation
US11019840B2 (en) * 2014-07-02 2021-06-01 R.J. Reynolds Tobacco Company Oral pouch products
US10959456B2 (en) 2014-09-12 2021-03-30 R.J. Reynolds Tobacco Company Nonwoven pouch comprising heat sealable binder fiber
US20160157515A1 (en) 2014-12-05 2016-06-09 R.J. Reynolds Tobacco Company Smokeless tobacco pouch
US20160192703A1 (en) * 2015-01-07 2016-07-07 R.J. Reynolds Tobacco Company Oral pouch products
US10881133B2 (en) 2015-04-16 2021-01-05 R.J. Reynolds Tobacco Company Tobacco-derived cellulosic sugar
US9918492B2 (en) 2015-05-14 2018-03-20 R.J. Reynolds Tobacco Company Treatment of tobacco
US11147309B2 (en) 2015-06-10 2021-10-19 R.J. Reynolds Tobacco Company Container for smokeless tobacco products comprising a pulp material and related packaged product assembly and method
CN105116837B (en) * 2015-07-13 2018-03-16 河北白沙烟草有限责任公司 A kind of filament cutter automatic speed regulation control method and equipment based on material volume weight Cumulate algorithm
US10499684B2 (en) 2016-01-28 2019-12-10 R.J. Reynolds Tobacco Company Tobacco-derived flavorants
US11154087B2 (en) 2016-02-02 2021-10-26 R.J. Reynolds Tobacco Company Method for preparing flavorful compounds isolated from black liquor and products incorporating the flavorful compounds
US11091446B2 (en) 2017-03-24 2021-08-17 R.J. Reynolds Tobacco Company Methods of selectively forming substituted pyrazines
US10470487B2 (en) 2017-04-06 2019-11-12 R.J. Reynolds Tobacco Company Smoke treatment
US10548347B2 (en) 2018-02-23 2020-02-04 American Snuff Company, Llc Container for smokeless tobacco products
DK3774570T3 (en) 2018-04-13 2022-05-23 Reynolds Tobacco Co R LID FOR A CONTAINER FOR SMOKE-FREE TOBACCO PRODUCTS AND METHOD FOR MANUFACTURE OF SUCH A LID
US20200196658A1 (en) 2018-12-20 2020-06-25 R.J. Reynolds Tobacco Company Method for whitening tobacco
US11213062B2 (en) 2019-05-09 2022-01-04 American Snuff Company Stabilizer for moist snuff
EP3979841B1 (en) * 2019-06-05 2023-04-19 Philip Morris Products S.A. Nicotine composition, method for making and aerosol generating articles comprising such
DK3773495T3 (en) * 2019-06-07 2023-01-16 Philip Morris Products Sa COMPOSITION OF NICOTINE POUCH
CN110384700A (en) * 2019-09-03 2019-10-29 云南喜科科技有限公司 A kind of composition synthesizing nicotine
CA3150662A1 (en) 2019-09-11 2021-03-18 Michael Andrew Zawadzki Alternative methods for whitening tobacco
US12063953B2 (en) 2019-09-11 2024-08-20 Nicoventures Trading Limited Method for whitening tobacco
US11369131B2 (en) 2019-09-13 2022-06-28 Nicoventures Trading Limited Method for whitening tobacco
US20210169138A1 (en) 2019-12-09 2021-06-10 Nicoventures Trading Limited Fibrous fleece material
CA3159813A1 (en) 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral product with dissolvable component
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
WO2021116842A1 (en) * 2019-12-09 2021-06-17 Nicoventures Trading Limited Oral products with controlled release
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
MX2022006980A (en) 2019-12-09 2022-08-25 Nicoventures Trading Ltd Pouched products with heat sealable binder.
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
GB202006143D0 (en) * 2020-04-27 2020-06-10 Nonwovenn Ltd Nonwoven fabric for oral pounched product, and methods of manufacturing a nonwoven fabric
US11937626B2 (en) 2020-09-04 2024-03-26 Nicoventures Trading Limited Method for whitening tobacco
EP4284972A1 (en) 2021-01-28 2023-12-06 Nicoventures Trading Limited Method for sealing pouches
CA3238147A1 (en) 2021-11-15 2023-05-19 Christopher Keller Products with enhanced sensory characteristics
WO2023194959A1 (en) 2022-04-06 2023-10-12 Nicoventures Trading Limited Pouched products with heat sealable binder
US20240109697A1 (en) 2022-10-03 2024-04-04 Nicoventures Trading Limited Sealing member for packaging
WO2024074988A1 (en) 2022-10-04 2024-04-11 R. J. Reynolds Tobacco Company Stackable arrangement of product containers and related method of stacking
WO2024079696A1 (en) 2022-10-14 2024-04-18 Nicoventures Trading Limited Apparatus and method for manufacturing and inspecting a pouched product or at least one object associated therewith
WO2024079697A1 (en) 2022-10-14 2024-04-18 Nicoventures Trading Limited Apparatus and method for manufacturing a pouched product

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1243507A (en) * 1968-03-13 1971-08-18 British Petroleum Co Ultrafiltration separation process
US3757798A (en) * 1972-01-03 1973-09-11 W Lambert Method of reducing dependence on tobacco
US4666991A (en) * 1984-11-05 1987-05-19 Sagami Chemical Research Center Fluorine-containing graft copolymer and adhesive and composite membrane made thereof
DK169616B1 (en) * 1986-08-27 1994-12-27 Dow Danmark Permeable, porous, polymer-treated plastic membrane with hydrophilic character, processes for their preparation and use thereof
US4975270A (en) * 1987-04-21 1990-12-04 Nabisco Brands, Inc. Elastomer encased active ingredients
JPH01108966A (en) * 1987-10-22 1989-04-26 Kowa Display:Kk Snuff
US4941484A (en) * 1989-05-30 1990-07-17 R. J. Reynolds Tobacco Company Tobacco processing
US5069231A (en) * 1989-07-12 1991-12-03 International Flavors & Fragrances Inc. Method for imparting functional ingredients, functional ingredient-imparting articles and methods for preparation and use thereof
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
EP0540623B1 (en) * 1990-07-23 1994-09-14 Alza Corporation Oral osmotic device for delivering nicotine
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5372149A (en) * 1992-03-25 1994-12-13 Roth; David S. Sterilization process in the manufacturing of snuff
US5465739A (en) * 1992-04-15 1995-11-14 R. J. Reynolds Tobacco Company Cigarette and cigarette filter element therefor
US5346734A (en) * 1993-04-16 1994-09-13 Bethanie K. Wydick Perforated latex oral pouch for loose snuff
US5387416A (en) * 1993-07-23 1995-02-07 R. J. Reynolds Tobacco Company Tobacco composition
IE72523B1 (en) * 1994-03-10 1997-04-23 Elan Med Tech Nicotine oral delivery device
AU7662796A (en) * 1995-10-11 1997-04-30 Dedric M. Derr System and method for protecting oral tissues from smokeless tobacco

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008038556A1 (en) * 2008-06-26 2009-12-31 Eswegee Vliesstoff Gmbh Nonwoven fabric for use as a moisture-permeable, microporous semi-luxury packaging material

Also Published As

Publication number Publication date
US20050061339A1 (en) 2005-03-24
AU2002360097A8 (en) 2003-07-09
DE60224832T2 (en) 2009-01-22
DE60224832D1 (en) 2008-03-13
EP1458252A2 (en) 2004-09-22
DK1458252T3 (en) 2008-05-13
WO2003053175A3 (en) 2003-10-09
ATE384450T1 (en) 2008-02-15
AU2002360097A1 (en) 2003-07-09
WO2003053175A2 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
EP1458252B1 (en) Tobacco and/or tobacco in combination with tobacco substitute composition for use as a snuff in the oral cavity
JP5694645B2 (en) Improved snuff composition
EP1617823B1 (en) A pouch comprising a nicotine composition for transmucosal delivery
US8846075B2 (en) Composition material for transmucosal delivery
DK2691096T3 (en) Bag containing free nicotine in salt form
ES2321721T3 (en) NICOTINE FORMULATIONS AND USE OF THE SAME.
EP3833315B1 (en) A pouch product suitable for application in an oral cavity
US20050034738A1 (en) Chewing tobacco substitute containing nicotine
EP3993646B1 (en) An oral pouched nicotine product including a filling material comprising nicotine-containing particles
WO2021099571A1 (en) An oral pouched nicotine product including a filling material comprising nicotine particles
CN107744174A (en) For the preparation and part being added in tobacco product
CA2868445C (en) Nicotine formulation
EP3868222A1 (en) Smokeless article
US20060112965A1 (en) Chewing tobacco substitute containing cotinine
EP4106556A1 (en) Smokeless article
EP3868223A1 (en) Smokeless article
RU2779390C1 (en) Packaged product suitable for application in the oral cavity
US20220386685A1 (en) Smokeless article

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040721

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SPEGEL, CHRISTER

Inventor name: HANSSON, HENRI

Inventor name: HOVGAARD, LARS

RTI1 Title (correction)

Free format text: TOBACCO AND/OR TOBACCO IN COMBINATION WITH TOBACCO SUBSTITUTE COMPOSITION FOR USE AS A SNUFF IN THE ORAL CAVITY

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60224832

Country of ref document: DE

Date of ref document: 20080313

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Ref country code: SE

Ref legal event code: TRGR

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080504

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080423

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080623

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20081024

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081231

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20081217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080424

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20131230

Year of fee payment: 12

Ref country code: DK

Payment date: 20131230

Year of fee payment: 12

Ref country code: GB

Payment date: 20131230

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20131230

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140102

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20131231

Year of fee payment: 12

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60224832

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20141231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141218

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141217

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20141217

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20150831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141217

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20141231